Suggested Remit - To appraise the clinical and cost-effectiveness of tagraxofusp within its marketing authorisation for treating patients with blastic plasmacytoid dendritic cell neoplasm
Status In progress
Process STA 2018
ID number 1556

Provisional Schedule

Committee meeting: 1 12 January 2021
Expected publication 24 March 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Stemline Therapeutics (tagraxofusp)
Others Department of Health and Social Care
  NHS England
  NHS Corby CCG
  NHS Erewash CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (azacitidine, cytarabine, fludarabine, idarubicin)
  Celgene (azacitidine)
  Chugai Pharma UK (lenograstim)
  Pfizer (cytarabine, idarubicin)
  Sanofi (fludarabine)
  Seacross Pharmaceuticals (azacitidine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Hospital Information Services – Jehovah’s Witnesses
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Blood and Transplant
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
07 May 2020 Invitation to participate
28 November 2019 This appraisal will be rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation as no NICE recommendation will be made at that point. For information, this appraisal is now anticipated to begin during early May 2020 when we will write to you about how you can get involved.
07 October 2019 (10:00) Scoping workshop (Manchester)
16 August 2019 - 16 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress. Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance